Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Nov 9;36(45):11402-11410.
doi: 10.1523/JNEUROSCI.2335-16.2016.

Current Perspectives in Autism Spectrum Disorder: From Genes to Therapy

Affiliations
Review

Current Perspectives in Autism Spectrum Disorder: From Genes to Therapy

Maria Chahrour et al. J Neurosci. .

Abstract

Autism spectrum disorder (ASD) is a constellation of neurodevelopmental presentations with high heritability and both phenotypic and genetic heterogeneity. To date, mutations in hundreds of genes have been associated to varying degrees with increased ASD risk. A better understanding of the functions of these genes and whether they fit together in functional groups or impact similar neuronal circuits is needed to develop rational treatment strategies. We will review current areas of emphasis in ASD research, starting from human genetics and exploring how mouse models of human mutations have helped identify specific molecular pathways (protein synthesis and degradation, chromatin remodeling, intracellular signaling), which are linked to alterations in circuit function and cognitive/social behavior. We will conclude by discussing how we can leverage the findings on molecular and cellular alterations found in ASD to develop therapies for neurodevelopmental disorders.

Keywords: animal models; autism spectrum disorder; genetics; therapeutics.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
The complex path from gene identification to therapy development in ASD. Although the ideal path from gene identification to therapy development via animal models appears linear (A), genetic and phenotypic heterogeneity prevents therapeutic advances in ASD and other complex disorders. Possible therapies will need to be customized based on the specific underlying molecular changes for subcategories that are still in the process of being defined (B). Combination approaches (e.g., multiple compounds targeting different mechanisms or endophenotypes) may also be necessary.

References

    1. Abrahams BS, Geschwind DH. Advances in autism genetics: on the threshold of a new neurobiology. Nat Rev Genet. 2008;9:341–355. doi: 10.1038/nrg2346. - DOI - PMC - PubMed
    1. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, Kondrashov AS, Sunyaev SR. A method and server for predicting damaging missense mutations. Nat Methods. 2010;7:248–249. doi: 10.1038/nmeth0410-248. - DOI - PMC - PubMed
    1. Adzhubei I, Jordan DM, Sunyaev SR. Predicting functional effect of human missense mutations using PolyPhen-2. Curr Protoc Hum Genet Chapter. 2013;7 doi: 10.1002/0471142905.hg0720s76. Unit 7.20. - DOI - PMC - PubMed
    1. Alexander MS, Gasperini MJ, Tsai PT, Gibbs DE, Spinazzola JM, Marshall JL, Feyder MJ, Pletcher MT, Piatnitski Chekler EL, Morris CA, Sahin M, Harms JF, Schmidt CJ, Kleiman RJ, Kunkel LM. Reversal of neurobehavioral social deficits in dystrophic mice using inhibitors of phosphodiesterases PDE5A and PDE9A. Transl Psychiatry. 2016 in press. - PMC - PubMed
    1. Anderson JL, Head SI, Morley JW. Altered inhibitory input to Purkinje cells of dystrophin-deficient mice. Brain Res. 2003;982:280–283. doi: 10.1016/S0006-8993(03)03018-X. - DOI - PubMed

MeSH terms